Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company focusing on precision oncology through synthetic lethality, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY.
Dr. Oren Gilad, President and CEO of Aprea, will deliver a corporate update during the conference. The presentation will be available on-demand starting at 7:00 A.M. (ET) on September 9, 2024, and will remain accessible for 90 days. Interested parties can access the webcast through a provided link.
Additionally, Aprea's management team will be available for one-on-one meetings with institutional investors during the conference. Attendees interested in scheduling a meeting are advised to contact their conference representative.
Aprea Therapeutics (Nasdaq: APRE), una compagnia biofarmaceutica in fase clinica che si concentra sull'oncologia di precisione attraverso la letalità sintetica, ha annunciato la sua partecipazione alla 26a Conferenza Globale di Investimento Annuale H.C. Wainwright. L'evento è programmato per dal 9 all'11 settembre 2024 a New York, NY.
Il Dr. Oren Gilad, Presidente e CEO di Aprea, presenterà un aggiornamento aziendale durante la conferenza. La presentazione sarà disponibile on-demand a partire dalle 7:00 A.M. (ET) del 9 settembre 2024 e rimarrà accessibile per 90 giorni. Le parti interessate possono accedere al webcast tramite un link fornito.
Inoltre, il team di gestione di Aprea sarà disponibile per incontri one-on-one con investitori istituzionali durante la conferenza. I partecipanti interessati a pianificare un incontro sono invitati a contattare il loro rappresentante della conferenza.
Aprea Therapeutics (Nasdaq: APRE), una empresa biofarmacéutica en etapa clínica centrada en la oncología de precisión a través de la letalidad sintética, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento está programado para del 9 al 11 de septiembre de 2024 en Nueva York, NY.
El Dr. Oren Gilad, Presidente y CEO de Aprea, ofrecerá una actualización corporativa durante la conferencia. La presentación estará disponible bajo demanda a partir de 7:00 A.M. (ET) del 9 de septiembre de 2024 y permanecerá accesible durante 90 días. Las partes interesadas pueden acceder a la transmisión web a través de un enlace proporcionado.
Además, el equipo de gestión de Aprea estará disponible para reuniones uno a uno con inversores institucionales durante la conferencia. Se aconseja a los asistentes interesados en programar una reunión que se pongan en contacto con su representante de la conferencia.
Aprea Therapeutics (Nasdaq: APRE)는 합성 치사성을 통한 정밀 종양학에 집중하는 임상 단계의 바이오 제약 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참가한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 개최됩니다.
Aprea의 사장 겸 CEO인 Dr. Oren Gilad가 회의 중 기업 업데이트를 발표할 예정입니다. 발표는 2024년 9월 9일 오전 7시 (Eastern Time)부터 주문형으로 제공되며, 90일 동안 접근할 수 있습니다. 관심 있는 사람들은 제공된 링크를 통해 웹캐스트에 접속할 수 있습니다.
또한 Aprea의 경영진은 회의 중 기관 투자자와의 일대일 미팅을 위해 준비되어 있습니다. 미팅 일정을 잡고자 하는 참석자는 회의 대표에게 연락해주실 것을 권장합니다.
Aprea Therapeutics (Nasdaq: APRE), une entreprise biopharmaceutique en phase clinique axée sur l'oncologie de précision par le biais de la létalité synthétique, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à New York, NY.
Le Dr Oren Gilad, Président et CEO d'Aprea, présentera une mise à jour sur l'entreprise lors de la conférence. La présentation sera disponible à la demande à partir de 7h00 (ET) le 9 septembre 2024 et restera accessible pendant 90 jours. Les parties intéressées peuvent accéder au webinaire via un lien fourni.
De plus, l'équipe de direction d'Aprea sera disponible pour des réunions en tête-à-tête avec des investisseurs institutionnels pendant la conférence. Les participants intéressés par la planification d'une rencontre sont invités à contacter leur représentant de conférence.
Aprea Therapeutics (Nasdaq: APRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Onkologie durch synthetische Letalität konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung ist für vom 9. bis 11. September 2024 in New York, NY, geplant.
Dr. Oren Gilad, Präsident und CEO von Aprea, wird während der Konferenz ein Unternehmensupdate geben. Die Präsentation wird ab 7:00 Uhr (ET) am 9. September 2024 auf Abruf verfügbar sein und 90 Tage lang zugänglich bleiben. Interessierte können über einen bereitgestellten Link auf das Webcast zugreifen.
Darüber hinaus wird das Management-Team von Aprea während der Konferenz für Einzelgespräche mit institutionellen Investoren zur Verfügung stehen. Teilnehmende, die ein Treffen vereinbaren möchten, werden gebeten, ihren Konferenzvertreter zu kontaktieren.
- None.
- None.
DOYLESTOWN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
| Date: | September 9-11, 2024 |
| Location: | New York, NY |
| Webcast: | click here |
The above presentation is available to access “on-demand”, beginning at 7:00 A.M. (ET), on September 9, 2024. It will be available for 90 days.
Management will be available for one-on-one meetings with institutional investors. To request a meeting, please contact your conference representative.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
When is Aprea Therapeutics (APRE) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting the corporate update for Aprea Therapeutics (APRE) at the conference?
How can investors access Aprea Therapeutics' (APRE) presentation at the H.C. Wainwright conference?
Will Aprea Therapeutics (APRE) management be available for meetings during the conference?
